Home Tags HydraSpace

Tag: HydraSpace

Emergence Therapeutics Becomes the 10th Company to License Synaffix’ ADC Platform...

In a statement earlier today, Dutch-biotech Synaffix and German Emergence Therapeutics announced that the Companies have entered into a licensing agreement of up to...

Kyowa Kirin Expands License Agreement with Synaffix

Japanese pharmaceutical and biotechnology company Kyowa Kirin has expanded its license agreement with The Netherlands based Synaffix with one new antibody-drug conjugates (ADC) target added to...

Novel Linker-Drug Technology Enables Antibody-Drug Conjugates with an Expanded Therapeutic Window

Preclinical data from a novel, proprietary ADC technology platform being developed by ProfoundBio was being presented at the 2021 Molecular Targets and Cancer Therapeutics...

Synaffix and ADC Therapeutics Expand Collaboration

The Netherlands-based biotechnology company Synaffix and Swiss-based ADC Therapeutics have expanded the existing collaboration between the companies to explore additional applications of Synaffix’ site-specific...
Featured Image - Laboratory. Courtesy 2019 Fotolia

Shanghai Miracogen and Synaffix Confirm Expansion of License Agreement

Netherlands-based biotech company Synaffix earlier today confirmed the expansion of a license agreement with Shanghai Miracogen, a Chinese biotechnology company with a clinical-stage pipeline...

Abzena Confirms Successful Technical Transfer of Synaffix’s GlycoConnect™ and HydraSpace™ Technologies

Earlier today Abzena confirmed that it had successfully completed a technology transfer and scalability evaluation using the Synaffix's technologies of GlycoConnect™, site-specific antibody-drug conjugation...
Scientist pipetting

ADC Therapeutics Expands Agreement with Synaffix

The Netherlands-based biotechnology company Synaffix, which develops clinical-stage technologies for the development of best-in-class antibody-drug conjugates or ADCs, confirmed that ADC Therapeutics has triggered...

Dutch Biotech Signs License Agreement with Chinese ADC Developer

The Dutch biotech company Synaffix has signed a license agreement with the Chinese ADC developer Shanghai Miracogen. The agreement is estimated to be worth...

New ADC Payload Platform – Synaffix Launches toxSYN™

The Netherlands-based biotech company Synaffix, which has developed a proprietary site-specific conjugation platform technology to enable differentiated antibody-drug conjugates or ADCs, launched of a...

Synaffix Secures End-to-end Patent Protection for GlycoConnect Technology

The Netherlands-based Synaffix, a biotechnology company that has developed a proprietary site-specific platform technology to enable differentiated antibody-drug conjugates (ADCs), has received a key...

X